Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AstraZeneca plc; Foundation Medicine, Inc.; GRAIL, Inc.; Guardant Health, Inc.; and Eli Lilly and Company.

For further information concerning Lilly grant funding, visit

Medical Crossfire®: Novel Applications of Liquid Biopsies Across Cancer Care

Release Date: June 25, 2020
Expiration Date: June 25, 2021

Activity Overview

The advent of improved sequencing technologies and platforms has rapidly expanded the understanding of genomic alterations that drive tumor biology. Accordingly, in recent decades, there have been numerous targeted agents for individual alterations introduced as treatment options across solid tumors, and there are many more agents in ongoing clinical trials. Clinicians treating patients with solid tumors, especially lung, breast, and gastrointestinal malignancies, are faced with the challenge of determining how and when to perform molecular testing on their patients and how to use that information to optimize treatment planning.

This online, on-demand virtual symposium brings together a renowned expert faculty panel to review emerging data and new treatment options for patients with targetable molecular alterations. Key topics include how to use blood-based tests for diagnosis and treatment planning, how liquid biopsy can aid in monitoring response or identifying resistance mechanisms and emerging targeted therapeutics. An interactive Medical Crossfire® discussion in the context of clinical scenarios will aid in applying new data to the care of your patients.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AstraZeneca plc; Foundation Medicine, Inc.; GRAIL, Inc.; Guardant Health, Inc.; and Eli Lilly and Company.

For further information concerning Lilly grant funding, visit

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Summarize the comparative advantages of currently available liquid-based and tissue-based testing approaches
  • Evaluate clinical data concerning new and emerging liquid biopsy technologies
  • Describe emerging uses of liquid biopsies across the spectrum of cancer care, including in non–small-cell lung cancer, breast cancer, and gastrointestinal cancers
  • Assess clinical evidence pertaining to specific testing modalities that may help to individualize treatment protocols for patients with cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Charu Aggarwal, MD, MPH
Charu Aggarwal, MD, MPH
Leslye M. Heisler Assistant Professor for Lung Cancer Excellence
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: AstraZeneca, Celgene, Eli Lilly, Merck, Roche.

Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH
Director, Precision Medicine, Center for Breast Cancer
Assistant Professor of Medicine, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: Genentech/Roche (institution), Immunomedics (institution), Novartis (institution), Pfizer (institution), Merck (institution), Radius Health (institution), Sanofi (institution), Mersana (institution), Daiichi/AstraZeneca (institution); Consultant: Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Sanofi, Daiichi/AstraZeneca (institution).

Ryan B. Corcoran, MD, PhD
Ryan B. Corcoran, MD, PhD
Director, Gastrointestinal Cancer Center Program
Massachusetts General Hospital Cancer Center
Boston, MA

Disclosures: Grant Research Support: Asana, Lilly; Consultant: Array, Astex, Avidity, C4 Therapeutics, Elicio, Kinnate, Ipsen, Natera, N-of-One/Qiagen, nRichDx, Revolution Medicines, Roivant, Taiho, Zikani; Other: Avidity Biosciences, C4 Therapeutics, Kinnate Biopharma, nRichDx, Revolution Medicines.

Daniel B. Costa, MD, PhD, MMSc
Daniel B. Costa, MD, PhD, MMSc
Division of Medical Oncology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Nonfinancial support (institutional research support) from Merck Sharp & Dohme Corporation, Merrimack Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals and Tesaro, all outside the submitted work. DR reports nonfinancial support (institutional research support) from Bristol Myers Squibb, Novocure, and AbbVie/Stemcentrx; Consultant: Personal fees (consulting fees and honoraria) and nonfinancial support (institutional research support) from Takeda/Millennium Pharmaceuticals, AstraZeneca, and Pfizer.

Benjamin P. Levy, MD
Benjamin P. Levy, MD
Associate Professor of Oncology, Johns Hopkins University School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Grant Research Support: Turning Point, AstraZeneca, Eli Lilly, Genentech Roche; Consultant: AstraZeneca, Merck, Eli Lilly, Novartis, Pfizer, Genentech Roche, Guardant.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By